Public Health Resources

 

Date of this Version

2016

Citation

Clinical Infectious Diseases (2016) doi: 10.1093/cid/ciw256.

Comments

US government work

Abstract

From September 2014–April 2015, six persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agents rVSV-ZEBOV or TKM-100802 for post-exposure prophylaxis and were monitored in the U.S. All patients experienced self-limited symptoms after PEP; none developed Ebola virus disease.

Share

COinS